Zobrazeno 1 - 10
of 84
pro vyhledávání: '"O B, Karyakin"'
Autor:
I. O. Dementev, K. M. Nyushko, O. B. Karyakin, V. S. Chaikov, A. V. Troyanov, I. N. Zaborskii, E. O. Shchukina
Publikováno v:
Issledovaniâ i Praktika v Medicine, Vol 8, Iss 3, Pp 97-107 (2021)
Currently, due to the dynamic development of surgical technologies, indications for organ-sparing treatment of kidney cancer are expanding. Acute kidney injury is a serious complication that leads to chronic kidney disease, increased postoperative mo
Externí odkaz:
https://doaj.org/article/48d11c886e954c4bac9d5f8142251b56
Autor:
I. N. Zaborskii, K. N. Safiullin, O. B. Karyakin, S. A. Ivanov, V. S. Chaikov, I. O. Dementev, A. V. Sidorin, G. N. Grishin, A. N. Yurchenko
Publikováno v:
Issledovaniâ i Praktika v Medicine, Vol 7, Iss 2, Pp 129-143 (2020)
Abstract In recent years, there has been a steady increase in the incidence of bladder cancer (RMP) in our country. So, over the past ten years there has been an increase in the number of cases of primary diagnosis of RMP by more than 1.5 times, whic
Externí odkaz:
https://doaj.org/article/9f88dc42d3ff4023ade34942fd94a53e
Autor:
K. S. Makarova, Yu. V. Gumenetskaya, V. A. Biryukov, T. A. Rodina, A. B. Galitsyna, E. O. Shchukina, O. B. Karyakin, S. A. Ivanov, A. D. Kaprin
Publikováno v:
Cancer Urology. 19:76-84
Background. Currently, the group of intermediate risk prostate cancer (PC) includes 2 subgroups - favorable and unfavorable intermediate risk according to the National Comprehensive Cancer Network (NCCN) classification. The optimal scope of therapy i
Autor:
V. S. Chaykov, I. O. Dementyev, O. B. Karyakin, E. O. Shchukina, A. V. Troyanov, S. A. Ivanov, A. D. Kaprin
Publikováno v:
Cancer Urology. 19:25-34
Background. Renal cell carcinoma is one of the most common urologic cancers. Due to development of modern diagnostic methods, kidney tumors are often diagnosed at early stages (cT1a-T1b). The golden standard of treatment of localized renal cell carci
Autor:
K. S. Makarova, Yu. V. Gumenetskaya, V. A. Biryukov, A. A. Obukhov, I. A. Strikanova, S. O. Dzhabrailova, O. G. Lepilina, N. B. Borysheva, O. B. Karyakin, S. A. Ivanov, A. D. Kaprin
Publikováno v:
Сибирский онкологический журнал, Vol 18, Iss 2, Pp 15-21 (2019)
Purpose: to analyze toxicity of combined modality radiotherapy in high-risk prostate cancer patients.Material and methods. Short-term outcomes after combined modality radiotherapy were analyzed in 88 prostate cancer patients treated at clinic of the
Externí odkaz:
https://doaj.org/article/facfcd3c51244dd79335b21d6c277cc0
Autor:
A. V. Troianov, I. O. Dementev, I. N. Zaborsky, V. S. Chaykov, O. B. Karyakin, Yu. V. Gumenetskaya
Publikováno v:
Research and Practical Medicine Journal. 10:111-125
Purpose of the study. Generalization of the world experience of organ‑preserving treatment in muscle‑invasive bladder cancerMaterials and methods. The literature was searched in Medline, Cochrane Library, Elibrary and PubMed systems. Publications
Autor:
O. B. Karyakin
Publikováno v:
Cancer Urology. 18:141-146
This review presents the main lines of research on bladder cancer in 2021 and 2022. The review largely focuses on molecular studies in the context of primary diagnosis and disease progression. Based on molecular and genetic data, 3 main types of blad
Autor:
V. V. Krylov, N. S. Legkodimova, T. Yu. Kochetova, V. M. Petriev, M. A. Sigov, V. K. Tishchenko, A. I. Pronin, A. Yu. Shurinov, K. M. Petrosyan, O. N. Spichenkova, O. B. Karyakin, V. A. Biryukov, V. F. Stepanenko, O. P. Vlasova, P. V. Shegaj, S. A. Ivanov, A. D. Kaprin
Publikováno v:
Diagnostic radiology and radiotherapy. 13:75-85
INTRODUCTION: The results of studies of clinical potential of a new domestic radiopharmaceutical 177Lu-DOTA-PSMA in patients with metastatic castration-resistant prostate cancer are presented in this article.OBJECTIVE: The pharmacokinetics, safety an
Autor:
O. B. Karyakin, N. V. Vorobyov, I. N. Zaborskiy, A. G. Muradyan, K. N. Safiullin, I. A. Taraki, G. A. Demyashkin, S. A. Ivanov, A. D. Kaprin
Publikováno v:
Cancer Urology. 18:92-98
Background. Bladder cancer is the ninth most common malignant neoplasm worldwide. Hidden metastases at the time of diagnosis are the main reason muscle-invasive bladder cancer has poor prognosis. Even after radical cystectomy, muscleinvasive bladder
Autor:
A. A. Klimenko, I. P. Kostyuk, O. B. Karyakin, S. A. Moserov, Z. N. Shavladze, I. N. Zaborsky, V. S. Chaykov, M. E. Tarasova
Publikováno v:
Issledovaniâ i Praktika v Medicine, Vol 5, Iss 1, Pp 113-122 (2018)
This article presents a clinical observation of the treatment of recurrent invasive urothelial cancer of the upper urinary tract using surgical and chemotherapy treatments. During the treatment, surgical treatment and 2 chemotherapy lines were perfor
Externí odkaz:
https://doaj.org/article/ba543b37d3e84061aa67f40034fae566